共 50 条
- [1] Efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC) and brain metastases: Preliminary results from the GETUG-AFU 26 (Nivoren) study.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Escudier, Bernard J.Chabaud, SylvieBorchiellini, DelphineGravis, GwenaelleChevreau, ChristineBrachet, Pierre EmmanuelGeoffrois, LionnelLaguerre, BrigitteMahammedi, HakimNegrier, SylvieRolland, FredericGoupil, Marine GrossHabibian, MurielAlbiges, Laurence
- [2] Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): Final analysis from the NIVOREN GETUG AFU 26 study.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)Albiges, LaurenceNegrier, SylvieDalban, CecileChevreau, ChristineGravis, GwenaelleOudard, StephaneLaguerre, BrigitteBarthelemy, PhilippeBorchiellini, DelphineGross-Goupil, MarineGeoffrois, LionnelRolland, FredericThiery-Vuillemin, AntoineJoly, FlorenceLadoire, SylvainTantot, FlorenceEscudier, Bernard
- [3] Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 studyEUROPEAN JOURNAL OF CANCER, 2024, 201Mourey, LoicRainho, Larissa TamesDalban, CecileCarril-Ajuria, LuciaNegrier, SylvieChevreau, ChristineGravis, GwenaelleThibault, ConstanceLaguerre, BrigitteBarthelemy, PhilippeBorchiellini, DelphineGross-Goupil, MarineGeoffrois, LionnelRolland, FredericThiery-Vuillemin, AntoineTantot, FlorenceChaput, NathalieNaigeon, MarieTeixeira, MarcusEscudier, BernardFlippot, RonanAlbiges, Laurence
- [4] Primary tumour response in patients treated with nivolumab for metastatic renal cell carcinoma (mRCC): Results of the GETUG-AFU 26 NIVOREN trialANNALS OF ONCOLOGY, 2020, 31 : S560 - S560Courcier, J.Dalban, C.Laguerre, B.Ladoire, S.Barthelemy, P.Oudard, S.Joly, F.Mescam, G. GravisChevreau, C. M.Geoffrois, L.Deluche, E.Rolland, F.Topart, D.Culine, S.Negrier, S.Mahammedi, H.Tantot, F.Escudier, B.Flippot, R.Albiges, L.
- [5] Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II StudyJOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (23) : 2008 - +Flippot, RonanDalban, CecileLaguerre, BrigitteBorchiellini, DelphineGravis, GwenaelleNegrier, SylvieChevreau, ChristineJoly, FlorenceGeoffrois, LionnelLadoire, SylvainMahammedi, HakimRolland, FredericGross-Goupil, MarineDeluche, ElisePriou, FrankLaramas, MathieuBarthelemy, PhilippeNarciso, BerengereHouede, NadineCuline, StephaneOudard, StephaneChenot, MarinaTantot, FlorenceChabaud, SylvieEscudier, BernardAlbiges, Laurence
- [6] Baseline circulating soluble factors as predictors of response to nivolumab in metastatic clear cell renal cell carcinoma (mRCC): A validation study within the NIVOREN GETUG-AFU 26 translational study.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Carril-Ajuria, LuciaNaigeon, MarieDalban, CecileDesnoyer, AudeRioux-Leclercq, NathalieSautes-Fridman, CatherineMeylan, MaximeVano, Yann-AlexandreBeusenlick, BenoitChouaib, SalemDe Oliveira, CarolineTantot, FlorenceFlippot, RonanEscudier, BernardAlbiges, LaurenceChaput, Nathalie
- [7] Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II StudyCLINICAL GENITOURINARY CANCER, 2022, 20 (05) : 488 - 494Rassy, ElieDalban, CecileColomba, EmelineDerosa, LisaSilva, Carolina Alves CostaNegrier, SylvieChevreau, ChristineGravis, GwenaelleOudard, StephaneLaguerre, BrigitteBarthelemy, PhilippeGoupil, Marine GrossGeoffrois, LionnelRolland, FredericThiery-Vuillemin, AntoineJoly, FlorenceLadoire, SylvainTantot, FlorenceEscudier, BernardAlbiges, Laurence
- [8] Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN TrialEUROPEAN UROLOGY, 2021, 80 (03) : 325 - 329Courcier, JeanDalban, CecileLaguerre, BrigitteLadoire, SylvainBarthelemy, PhilippeOudard, StephaneJoly, FlorenceGravis, GwenaelleChevreau, ChristineGeoffrois, LionelDeluche, EliseRolland, FredericTopart, DelphineCuline, StephaneNegrier, SylvieMahammedi, HakimTantot, FlorenceJamet, AntoineEscudier, BernardFlippot, RonanAlbiges, Laurence
- [9] Efficacy and safety of nivolumab in renal cell carcinoma patients with BONE metastases: Results of the GETUG: AFU 26 nivoren multicenter phase II study.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)Velev, MaudDalban, CecileChevreau, ChristineGravis, GwenaelleNegrier, SylvieLaguerre, BrigitteGross-Goupil, MarineLadoire, SylvainFerrari, VictoriaGeoffrois, LionnelCurcio, HubertPriou, FrankThomas, Quentin DominiqueMione, CecileBarthelemy, PhilippeTantot, FlorenceEscudier, BernardChabaud, SylvieAlbiges, LaurenceThibault, Constance
- [10] Antibiotic (ATB) therapy and outcome from nivolumab (N) in metastatic renal cell carcinoma (mRCC) patients (pts): Results of the GETUG-AFU 26 NIVOREN multicentric phase II studyANNALS OF ONCOLOGY, 2021, 32 : S681 - S681Derosa, L.Silva, C. Alves CostaDalban, C.Colomba, E.Negrier, S.Chevreau, C. M.Gravis, G.Oudard, S. M.Laguerre, B.Barthelemy, P.Borchiellini, D.Gross-Goupil, M.Geoffrois, L.Rolland, F.Thiery-Vuillemin, A.Joly, F.Ladoire, S.Tantot, F.Escudier, B.Albiges, L.